Arthritis, a set of heterogeneous joint disorders involving inflammation of one or more joints, is a group of persistent and progressive diseases with a huge health and socio-economic impact worldwide. Improving arthritis management requires to improve the early arthritis (EA) differential diagnosis and improve the adequacy of the therapeutic strategies.
RheumaKit: undifferentiated arthritis diagnosis
Our first marketed product is RheumaKit, an innovative solution for the differential diagnosis of patients with Undifferentiated Arthritis. The solution combines a sample collection and transportation kit, a centralized laboratory process in order to extract a transcriptomic signature from the patient sample, and a web-based application with an embedded predictive model. The solution is CE-marked for differential diagnostic application, while theranostic applications are in development (see illustration below and next paragraph). RheumaKit development also benefits from an H2020 SME Instrument project: ADDITION, standing for “Arthritis Differential DIagnosis and Theranosis validatION”.
RheumaKit in DMARDs clinical trials
Our signature for undifferentiated arthritis diagnosis contains several genes involved in various metabolic pathways of primary importance in the field of Rheumatoid Arthritis. They are important either because they relate to underlying disease mechanisms, or because they shed light on a priori treatments efficacy. Although in a less advanced validation stage than our diagnosis application (no CE marking), this application is well suited for companies developing or trying to validate disease-modifying anti-rheumatic drugs (DMARDs).
Download our Borchure on RheumaKit in DMARDs trials.